Mantle cell lymphoma and small lymphocytic lymphoma are lymphocyte cancers that have similar morphologies and a common age of onset. Mantle cell lymphoma is generally an aggressive B cell lymphoma with a short median survival time, whereas small lymphocytic lymphoma is typically an indolent B cell lymphoma with a prolonged median survival time. Using primary tumor samples in bi-directional suppression subtractive hybridization, we identified genes with differential expression in an aggressive mantle cell lymphoma versus an indolent small lymphocytic lymphoma. "Virtual" Northern blot analyses of multiple lymphoma samples confirmed that a set of genes was preferentially expressed in aggressive mantle cell lymphoma compared to indolent small lymphocytic lymphoma. These analyses identified mantle cell lymphoma-specific genes that may be involved in the aggressive behavior of mantle cell lymphoma and possibly other aggressive human lymphomas. Interestingly, most of these differentially expressed genes have not been identified using other techniques, highlighting the unique ability of suppression subtractive hybridization to identify potentially rare or low expression genes.
Introduction
Mantle cell lymphoma (MCL) is a B cell lymphoma derived from naïve, pre-germinal center B cells of the primary lymphoid follicles or the mantle zone of secondary lymphoid follicles (Campo et al., 1999; Perez-Galan et al., 2010) . MCL is typically characterized by an aggressive disease course that is unresponsive to conventional therapies, with a short median survival time of only three to four years (Campo et al., 1999; Decaudin, 2002; Hartmann et al., 2009; Leonard et al., 2001 ). The range of survival time can be as little as a few months to more than ten years (Hartmann et al., 2009 ). This rapid disease onset and fatal course is replicated in two recent MCL mouse models described below.
Abbreviations: BL, Burkitt lymphoma; CLL, chronic lymphocytic leukemia; DLBCL, diffuse large B cell lymphoma; EtBr, ethidium bromide; FL, follicular lymphoma; GC, germinal center; MCL, mantle cell lymphoma; MZL, marginal zone lymphoma; ORFs, open reading frames; SLL, small lymphocytic lymphoma; SSH, suppression subtractive hybridization; VN, virtual Northern. MCL is commonly characterized by a t(11;14) chromosomal translocation that juxtaposes the BCL-1 gene and the IgH gene enhancer and results in over expression of BCL-1 encoded Cyclin D1 proteins (Bertoni et al., 2004; Campo et al., 1999; Weisenburger et al., 1996) . Cyclin D1 transgenic mice however, do not develop lymphoid tumors (Bodrug et al., 1994; Lovec et al., 1994) , suggesting that additional genetic alterations are necessary for disease development. New mouse models of MCL have been developed by crossing IL-14␣ and c-MYC transgenic mice resulting in double transgenic mice that developed aggressive monoclonal tumors and resulted in death by lymphoma by four months of age (Ford et al., 2007) . In these mouse models, biomarkers and organ involvement are similar to that seen in human MCL (Ford et al., 2007) . A second mouse model was generated using SCID-hu immunodeficient mice as recipients of human patient MCL samples ). This mouse model also clinically showed organ involvement similar to the human disease .
Small lymphocytic lymphoma (SLL), the tissue counterpart of chronic lymphocytic leukemia (CLL), is a B cell lymphoma that is probably derived from either pre-or post-germinal center (GC) B cells (Klein et al., 2001; Rosenwald et al., 2001) . Pre-GC SLL lacks the genetic refinements observed in generating high-affinity antibodies during the GC reaction and can have a more aggressive clinical course than does post-GC SLL, which shows no genetic evidence of antibody gene alterations from passing through the GC (Klein and Dalla-Favera, 2008; Perez-Galan et al., 2010) . Unlike MCL and many other classes of lymphoma, pre-or post-GC CLL and SLL are not characterized by a common oncogenic translocation (Guipaud et al., 2003; Swerdlow et al., 1995) . Despite a poor response to conventional therapies, post-GC CLL/SLL is most often characterized by a prolonged indolent period with a median survival time between seven and ten years Dighiero et al., 1981) .
In this study, we identified differentially expressed genes that distinguish MCL from SLL. Bi-directional suppression subtractive hybridization (SSH) was performed between an aggressive MCL patient sample and an indolent SLL patient sample. Briefly, SSH is similar to mRNA differential display and subtractive cDNA hybridization techniques, comparing cDNA from a "tester" population of cells to mRNA or cDNA from a "driver" population (Diatchenko et al., 1996) . The advantage to SSH over many other methods is that non-target DNA amplification is specifically reduced, while amplification of the target population of differentially expressed cDNAs between the two samples is enhanced. Herein, several screening strategies were employed to reduce the number of false positive and non-tumorigenic clones from the cDNA pool prior to sequence identification and SSH identified a large number of differentially expressed genes in both MCL minus SLL (MCL-SLL) and SLL minus MCL (SLL-MCL) directions of the subtraction.
Differential expression of a subset of the "MCL-specific" genes (MCL-SLL subtraction) was further confirmed using "Virtual" Northern blot analyses with a larger panel of primary samples representing both aggressive and indolent human lymphomas. The "Virtual" Northern blot was utilized because the tissue samples were too small to use in a traditional Northern blot. The "Virtual" Northern used RT-PCR linear range generated cDNA of all expressed RNAs from each of the small tissue samples available (Teitell et al., 1999) . Thus, this study identified two sets of genes that are differentially expressed between MCL and SLL and a subset of genes that is differentially expressed between a larger panel of aggressive and indolent lymphoma samples. The diverse collection of "MCLspecific" genes potentially contribute to the aggressive behavior of MCL and provide candidate genes for MCL biomarkers and targets for therapeutics that combat aggressive human lymphomas.
Materials and methods

Patient samples
Five indolent lymphoma samples were used in this study. Three follicular lymphoma (FL), one marginal zone lymphoma (MZL), and one small lymphocytic lymphoma (SLL) patient samples were kindly provided by Jonathan W. Said (UCLA, Los Angeles, CA). Five aggressive lymphoma samples were used in this study. Two MCL patient samples were kindly provided by Jonathan W. Said (UCLA, Los Angeles, CA) and three MCL patient samples were kindly provided by Thomas M. Grogan (University of Arizona Cancer Center, Tucson, AZ). Samples were examined histologically and tissue blocks were trimmed to exclude areas of necrosis or surrounding non-lymphoid tissues. Microtome sections (5-10 m) were placed into 5 mL RNA Friendswood, TX) for total RNA extraction according to the manufacturer's instructions.
Suppression subtractive hybridization
cDNA was synthesized from 0.3 g total tumor RNA from one MCL patient sample and one SLL patient sample using the SMART PCR cDNA Synthesis Kit (Clontech, Palo Alto, CA) with 16 rounds of amplification. The resulting cDNA PCR products were each purified using the Qiaquick PCR purification kit (Qiagen, Valencia, CA). SSH to generate subtracted cDNA libraries from 1.3 g of pooled cDNA was performed essentially as described (Diatchenko et al., 1996) with reagents and procedures provided in the PCR-Select cDNA Subtraction kit (Clontech). Bi-directional suppression subtractive hybridization (SSH) was performed using MCL cDNA as tester and SLL cDNA as driver, and SLL cDNA as tester and MCL cDNA as driver. After the two hybridization steps (1st for 8 h and 2nd for 22 h), differential PCR products were generated by sequential amplifications (primary for 27 rounds and secondary for 12 rounds). The resulting differential cDNA populations were subcloned into the TOPO TA cloning vector pCR2.1 (Invitrogen, Carlsbad, CA) and transformed into DH5␣ Escherichia coli. White colonies containing gene inserts were selected by isopropyl-B-d-thiogalactoside/5-bromo-4-chloro-3-indolyl-B-galactoside screening and seeded into 96-well microtiter plates for growth with antibiotic selection. Approximately 1600 clones generated in the MCL-SLL direction and 900 clones generated in the SLL-MCL direction were randomly selected and grown in 96-well plates for further analysis. These subtracted populations were used as probes for miniarray screening, as described below.
Miniarray analysis
Samples of bacterial culture lysates in 96-well plates were stamped with the Multi-Blot Replicator replicating tool (V&P Scientific, San Diego, CA) into fresh 96-well Thermowell plates (Corning Costar, Lowell, MA) for PCR amplification of cDNA inserts. cDNA fragments were amplified by PCR using Advantage cDNA Polymerase Mix (Clontech) and Nested Primers 1 and 2 from the PCR-Select cDNA Subtraction kit. PCR was performed for 30 cycles (94 • C for 30 s, 68 • C for 3 min), and the average size of insert fragments was 1 kilobase as determined by ethidium bromide (EtBr) stained 1% agarose gels (data not shown). These PCR products were identically stamped onto quadruplicate MagnaCharge nylon membranes (Osmonics, Minnetonka, MN) using the Multi-Blot Replicator. The first position on each membrane was stamped with an 850-bp PstI fragment of the plant Lemna gibba RuBPCase gene. The membranes were denatured for 10 min in 0.5 M NaOH, 1 M NaCl and neutralized for 5 min in 0.5 M Tris pH8.0, 0.5 M NaCl, followed by UV crosslinking in a Spectrolinker (Specktronics, Westbury, NY). Miniarray analysis was performed as described (Patrone et al., 2003) using the following random-primed [␣-33 P]ATP (NEN, Boston, MA)-labeled probes generated using the Prime-It II Random Primer Labeling Kit (Stratagene, La Jolla, CA): (1) SLL cDNA; (2) MCL cDNA; (3) SLL-MCL subtracted cDNA population; (4) MCL-SLL subtracted cDNA population; (5) "common" gene cocktail; (6) L. gibba RuBPCase. Probes were spiked with 0.3 ng of the 850-bp RuBPCase gene fragment before radiolabeling to allow semi-quantitative comparisons of hybridization intensities between membranes. Hybridizations were performed in aqueous hybridization buffer (0.5 M NaPO 4 pH7.0, 1 mM EDTA, 7% SDS, 1% BSA) at 62 • C overnight. Membranes were washed three times with 0.1% SDS, 0.1× SSC at 62 • C for 15 min. Hybridization signals were determined visually by autoradiography and quantitatively with a PhosphorImager (GE Healthcare, Piscataway, NJ) by using the program IMAGEQUANT (GE Healthcare).
Sequencing and GenBank analysis
Sequencing of cDNA fragments was performed using cycle sequencing (Laragen, Los Angeles, CA) with T7 and M13Rev primers. Sequences were identified using GenBank's nucleotide and pro-tein databases and the BLAST algorithm. Clones were assigned to functional categories based on GeneCard information.
"Virtual" Northern blot analysis cDNA was synthesized from 0.2 to 0.7 g total tumor RNA from three FL, one MZL, one SLL, and five MCL patient samples using the SMART PCR cDNA Synthesis Kit (Clontech) essentially as described (Patrone et al., 2003) . After PCR amplification, cDNA was precipitated, washed, and resuspended in TNE (10 mM Tris pH8.0, 10 mM NaCl, 0.1 mM EDTA). cDNA concentrations were determined using the PicoGreen dsDNA Quantitation Reagent (Molecular Probes, Eugene, OR). 0.5 g cDNA was fractionated in 1% agarose gels in 1× TBE running buffer (equal lane loading was confirmed by ethidium bromide staining), denatured in 0.5 M NaOH, 1.5 M NaCl at RT for 30 min, neutralized in 0.5 M Tris pH7.0, 1.5 M NaCl at RT for 30 min, transferred to Nytran nylon membranes (Schleicher & Schuell, Keene, NH) using the TurboBlotter Rapid Downward Transfer System (Schleicher & Schuell) overnight in 10× SSC, and baked at 80 • C for 30 min.
cDNA fragments to be used as probes were prepared by PCR amplification of SSH-generated clones using Advantage cDNA Polymerase Mix and Nested Primers 1 and 2 under the following conditions: 94 • C for 1 min; 25 cycles of 94 • C for 15 s, 68 • C for 4 min; 68 • C for 8 min. Overnight digestion with Rsa I (Promega, Madison, WI) was performed to remove SSH linkers and reactions were then concentrated using the StrataPrep PCR Purification Kit (Stratagene, La Jolla, CA). PCR products were subsequently fractionated in 1% agarose gels, followed by agarose gel purification using Ultrafree-MC Centrifugal Filter Units (Millipore, Bedford, MA). DNA concentrations were determined by UV spectroscopy. Randomprimed [biotinylated]CTP-labeled probes were generated using the SpotLight Random Primer Labeling Kit (Clontech).
Probe hybridizations were performed individually using the SpotLight Chemiluminescent Hybridization & Detection Kit (Clontech). Hybridization signals were detected by chemiluminescence (Clontech). Membranes were stripped by incubating twice with 50 mL 0.4 M NaOH, 0.1% SDS at 60 • C for 15 min.
Results
To identify genes that are differentially expressed between MCL and SLL, we performed bi-directional SSH between an MCL patient sample and an SLL patient sample. RNA for SSH was extracted from tumor samples visually selected for a high proportion of tumorous versus non-tumorous or non-viable cells (Fig. 1) . Approximately 1600 clones from the MCL-SLL direction of the subtraction and approximately 900 clones from the SLL-MCL direction of the subtraction were analyzed. To reduce the number of false positives identified by SSH prior to sequencing analysis, we confirmed differential expression of clones through hybridization with cDNA starting material and subtracted material. For this purpose, dot-blot analyses of the SSH clones were performed using 96-well format. PCR-amplified cDNA was stamped onto membranes in duplicate and identical membranes were then hybridized with SLL cDNA, MCL cDNA, SLL-MCL subtracted cDNA, or MCL-SLL subtracted cDNA probes (data not shown). Clones showing differential expression in the appropriate direction of the subtraction were analyzed further.
Our previous work using SSH showed that a large number of identified clones are differentially expressed between two lymphocyte-derived tumor samples but are not likely to be involved in the tumorigenic process (Patrone et al., 2003; Teitell et al., 1999) . In order to minimize the analyses of these "common" genes in our study, additional dot-blot analyses were performed. PCR-amplified cDNA was stamped onto membranes in duplicate and the membranes were hybridized with the probe cocktail containing a variety of the "common" gene fragments not likely to be involved in the tumorigenic process (data not shown). SSH clones on the membranes showing detectable expression using this "common" gene cocktail were excluded from further analyses.
Clones showing differential expression and no "common" gene expression by dot-blot analyses were subsequently sequenced, analyzed using GenBank, and categorized according to function using GeneCard. A large number of genes involved in many different cellular processes were identified in both directions of the subtraction. Seventy-three different genes were identified in the MCL-SLL direction (Table 1) , and 131 different genes were identified in the SLL-MCL direction (Table 2 ). Since many genes were identified more than once, the identification frequency of each gene is included (Tables 1 and 2 ). The percentage of genes in each of the designated functional groups is shown in Figs. 2 and 3, where genes falling into multiple functional groups are included in each of these groups. It is interesting to note that while genes involved in immunity and signal transduction, for example, are similar in percentage, the aggressive, higher-rate of replication MCL has a significantly higher percentage of differential cell cycle-related and DNA damage and repair-related genes than were found to be differential in SLL (Figs. 2 and 3). Interestingly, the signature gene for MCL, cyclin D1 (CCND1), was not detected as differentially expressed between the MCL and SLL samples used. This is not surprising as the defining genetic alteration in MCL, a t(11;14)(q13;q32) translocation, does not massively overproduce transcripts encoding CCND1 (Gladkikh et al., 2010) , and the depth of our sequencing analyses may not have been deep enough to statistically detect this difference. More likely, CCND1 has sequence homology with other cyclin encoding genes, such as cyclin D2 (CCND2) and D3 (CCND3) (NCBI Genbank accession codes NM 001759.3 and NM 001760.3, with 73% and 71% identity respectively), and the SSH procedures could have artifactually eliminated this differentially expressed gene. Gratifyingly, another signature gene that distinguishes histologically indistinguishable SLL from MCL, CD23 (official name FCER2), was identified in SLL-specific genes and absent from the MCL-specific genes, further validating our SSH.
"Virtual" Northern blotting was performed on a subset of MCL-SLL genes in order to confirm differential expression between the tumor samples analyzed by SSH and to expand the analysis to include a larger panel of lymphoma samples. Since conventional Northern blotting could not be used due to limited primary sample RNAs, "Virtual" Northern blotting was performed in which total RNA was converted into cDNA and subsequently analyzed as a representation of the tumor RNA (Teitell et al., 1999) . All genes analyzed by "Virtual" Northern blot were differentially expressed between the SLL and MCL cases used in SSH (compare lanes 5 and 10 in all panels, Fig. 4 ), indicating successful performance of our SSH and dot-blot analyses. In addition, many of these genes showed broad differential expression across the larger panel of samples, including RBBP8, CCNB1, CCNB2, DCK, MCM7, RAD51AP1, NCOA4, SHOC2, SKAP2, and ZWINT. In contrast to the pattern of broad differential expression seen for many of these genes, CDC2, GPNMB, and GPR34 were only differentially expressed between the SSH tumor samples and showed variable expression across the larger panel of samples. The data from these "Virtual" Northern blots confirmed the differential expression of all genes analyzed and identified a subset of genes with preferential expression in typically aggressive versus indolent lymphoma.
Discussion
In order to identify genes that distinguish MCL and SLL, bidirectional SSH was performed and approximately 2500 clones were screened for differential expression using a variety of techniques. The combination of dot-blot analyses using SSH-generated probes and a "common" gene cocktail probe resulted in the successful removal of false positive and non-tumorigenic clones from the cDNA pool. After the completion of these screening techniques, 133 clones from the MCL-SLL direction and 179 clones from the SLL-MCL direction were sequenced and analyzed for identity using
GenBank. Non-redundant gene fragments were identified for 73 different genes in the MCL-SLL direction and 131 genes were identified in the SLL-MCL direction. The clustering of genes into functional group categories highlights the similarities, but more importantly the differences between typically aggressive lymphoma versus a typically indolent lymphoma gene profile. "Virtual" Northern blot analyses were performed on a subset of MCL-SLL genes and differ- ential expression between the tumor samples analyzed by SSH was confirmed for all genes tested. In addition, these "Virtual" Northern blot analyses expanded the study to include additional indolent FL and MZL patient samples and additional aggressive MCL patient samples, identifying genes with preferential expression in aggressive lymphoma. These genes include RBBP8, CCNB1, CCNB2, DCK, MCM7, RAD51AP1, NCOA4, SHOC2, SKAP2, and ZWINT. Many of these genes and several others have been identified in recent microarray analyses of MCL, SLL, CLL, FL, and other B cell lymphomas, both compared to each other and to normal tonsillar B cells. Interestingly, Table 1 , where genes are included in all categories in which they meet specific functional criteria according to GeneCard. Functional groups are graphed alphabetically and are by percentage as follows: other 17%, cell cycle 20%, DNA damage and repair 12%, immunity 11%, montochondria 10%, unknown function 9%, signal transduction 6%, unknown gene 5%, metastasis 4%, translation 4%, and oncogenesis 2%.
most of the differentially expressed genes identified here have not been found in other analyses, highlighting the unique ability of SSH to identify potentially rare or low expression genes (Gadgil et al., 2002) . When the differential genes identified in the MCL versus SLL and the SLL versus MCL SSH were categorized and displayed as a percentage of all differential genes found in the SSH, several interesting similarities and glaring differences were revealed (see Figs. 2 and 3 ). Functional categories with expected similar percentages of represented genes include those in immunity, signal transduction, translation, and those categorized as proteins with no currently designated function. The cancer-related gene frequency between the two SSH results were very similar with the MCL versus SLL SSH having 6% (as listed in Fig. 2 as metastasis and oncogenesis genes), and the SLL versus MCL SSH having 4% of the total genes fall into this category. It is notable to mention that the genes from the MCL versus SLL SSH functioned specifically in metastasis and oncogenesis, while the SLL versus MCL SSH genes were more loosely associated with cancer in general using GeneCard analysis. The categories that stand out as most different between MCL versus SLL SSH profiles are the cell cycle associated genes and the DNA damage and repair associated genes. None of the known genes Table 2 , where genes are included in all categories in which they meet specific functional criteria according to GeneCard. Functional groups are graphed alphabetically and are by percentage as follows: unknown gene 17%, immunity 14%, other 14%, transcription 12%, unknown function 11%, cytoskeleton 6%, mitochondria 5%, ribosomal 5%, cancer 4%, cell cycle 4%, signal transduction 4%, and translation 4%. found in the SLL versus MCL SSH were associated with DNA damage and repair, and only 4% of genes were associated with the cell cycle, as strongly contrasted with to 12% and 20% for MCL versus SLL SSH, respectively. These results are concordant with MCL being an aggressive, highly proliferative lymphoma (Jares and Campo, 2008) . Although a pre-GC MCL may show differences in gene expression compared with a post-GC SLL based on derivation from distinct stages of B cell lineage development, it is nevertheless striking that the cell cycle and DNA repair gene categories represent the most differentially expressed genes. Both pre-GC mantle zone cells and post-GC marginal zone cells are not thought to be rapidly cycling or undergoing active DNA damage, as compared with the highly proliferative and DNA-damage induced intervening GC B cell stage in development (Klein and Dalla-Favera, 2008) . Therefore, we favor the differential regulation of these gene regulatory packages as most likely arising from the pathology of rapid cell cycling with arrest and DNA damage known to occur in MCL versus SLL, rather than reflecting distinct cells/stages of origin. Finally, both SSH directions resulted in genes with unknown function and genes that have yet to be described, but there were significantly more (17% versus 5%) unknown genes found in the SLL versus MCL SSH directions for unclear reasons.
The subset of MCL-SLL genes analyzed by "Virtual" Northern blot was chosen for further analysis based on unknown biology or biol-ogy with a potential relevance to aggressive disease. CDC2 (cell division cycle 2, promoting G1 to S and G2 to M transitions) and CDC28A are cyclin-dependent kinases (Draetta and Beach, 1988; Draetta et al., 1988a Draetta et al., , 1988b Nurse, 1988, 1987; that interact with cyclin B1 Hunter, 1989, 1992) and cyclin B2 (Jackman et al., 1995) to drive entry into mitosis, and these complexes in turn interact with cyclin A and cyclin E to promote the G1/S transition Kaldis and Aleem, 2005) . Additionally, CDC2 appears to be the molecular target for G2 cell cycle arrest that occurs in response to DNA damage (Stark and Taylor, 2006) . CDC2 also functions in meiotic cell cycle control and causes arrested mammalian oocytes to reenter the cell cycle and complete meiosis (Han and Conti, 2006) . RBBP8 (retinoblastoma binding protein 8), also called RIM and CTIP, is a transcriptional corepressor that interacts with Rb (Fusco et al., 1998; Meloni et al., 1999) , BRCA1 (Li et al., 1999; Wong et al., 1998; Yu et al., 1998) , and IKAROS (Koipally and Georgopoulos, 2002) . RBBP8 is required for double strand break repair by homologous recombination in S phase and G2 (Huertas and Jackson, 2009; Limbo et al., 2007) . Specifically, RBBP8 must interact with BRCA1 to drive double strand break repair by homologous recombination (Yun and Hiom, 2009) which may be required to repair replication-related DNA damage in rapidly cycling MCL cells. DCK (deoxycytidine kinase) is found at high levels in normal mononuclear leukocytes and may be found at lower levels in non-lymphoid tissues with high levels of DCK found in corresponding tumors of these tissues (Eriksson et al., 1994) . The physiologic function of DCK is to phosphorylate several deoxyribonucleosides, dA, dC, and dG (Arner and Eriksson, 1995; Hazra et al., 2009 ) and also to activate several antileukemic nucleoside analogues (Smal et al., 2007) . Decreased expression of DCK is associated with resistance to anticancer chemotherapeutic agents (Chottiner et al., 1991; Kobayashi et al., 1994; Song et al., 2009) . GPNMB (glycoprotein non-metastatic melanoma protein B) is a transmembrane glycoprotein that has increased expression in low-metastatic melanoma cell lines (Weterman et al., 1995) , primary dendritic cells (Ahn et al., 2002) , glioma cells (Kuan et al., 2006) , melanoma cells (Tse et al., 2006) , macrophage-related tissues (Ripoll et al., 2007) , aggressive bone metastatic breast cancer cells , and in melanocytes and melanoblasts (Loftus et al., 2009; Tomihari et al., 2009) . GPNMB has a variety of ascribed functions including suppression of macrophage inflammatory responses (Ripoll et al., 2007) , the adhesion of melanocytes to keratinocytes (Tomihari et al., 2009) , and increases breast cancer metastasis to bone in a mouse model . GPR34 (G protein-coupled receptor 34), a P2Y-like receptor, is ubiquitously expressed (Schoneberg et al., 1999b) , but predominately in the brain (Bedard et al., 2007; Marchese et al., 1999b) , and is a G protein-coupled receptor of unknown function (Marchese et al., 1999a; Schoneberg et al., 1999a) . MCM7 (minichromosome maintenance complex component 7), is a component of the DNA replication machinery (Fujita et al., 1996a; Fujita et al., 1996b) and has increased expression in a variety of tumor tissues including neuroblastoma, prostate, cervical, endometrial, oral squamous cell, and hypopharyngeal carcinomas (Cromer et al., 2004; Feng et al., 2008; Hiraiwa et al., 1997; Li et al., 2005; Ren et al., 2006) . In a mouse model, MCM7 played a role in the initial formation of tumor and more importantly in their progression to malignant tumors (Honeycutt et al., 2006) . RAD51AP1 (RAD51 associated protein 1), also called PIR51, is a protein that interacts with RAD51, DNA, and RNA (Kovalenko et al., 1997; Mizuta et al., 1997) . RAD51AP1 plays a role in DNA repair by preventing chromosomal breaks (Henson et al., 2006) through the enhancement of RAD51 recombinase (Wiese et al., 2007) . RAD51AP1 has increased expression in primary hepatocellular carcinoma (Song et al., 2004) and is implicated in both the development and progression of intrahepatic cholangiocarcinoma (Obama et al., 2008) . NCOA4 (nuclear receptor coactivator 4) interacts with the androgen receptor (Gao et al., 1999) and is translocated to the RET oncogene in thyroid carcinoma (Peng et al., 2008 ). NCOA4 appears to promote cell growth and invasion of prostate cancer cells (Peng et al., 2008) . SHOC2 (soc-2 suppressor of clear homolog) is a positive regulator of Rasmediated signal transduction Sieburth et al., 1998) and specifically activates the MAPK pathway (Rodriguez-Viciana et al., 2006) to drive cell proliferation. SKAP2 (src kinase associated phosphoprotein 2) functions as an adaptor protein for the src family of kinases (Kouroku et al., 1998; Liu et al., 1998; Marie-Cardine et al., 1998) and is implicated in myeloid differentiation and growth arrest (Curtis et al., 2000) . ZWINT (ZW10 interactor) interacts with the kinetochore during mitosis, is required for proper chromosome segregation (Famulski et al., 2008; Kops et al., 2005; Lin et al., 2006; Starr et al., 2000; Wang et al., 2004) and is essential for mitotic spindle checkpoint control.
Several genes identified in the MCL-SLL SSH have also been identified in microarray studies (see Table 1 ). For example, TOP2A (topoisomerase II alpha) has been identified by microarray analyses as a component of an MCL proliferation signature (Rosenwald et al., 2003) and an MCL gene cluster (Thieblemont et al., 2004) , by protein microarray analysis as a protein with upregulated expression in MCL compared to normal tonsillar B cells (Ghobrial et al., 2005) , and by immunohistochemistry as a prognostic factor in MCL (Schrader et al., 2004) . TOP2A was identified in additional microarray studies as a gene with downregulated expression in CLL compared to normal tonsillar B cells (Aalto et al., 2001 ) and compared to diffuse large B cell lymphoma (DLBCL), Burkitt lymphoma (BL), and FL (Klein et al., 2001) . GPNMB was identified as a gene with significantly upregulated expression in MCL compared to normal B cell populations (Ek et al., 2002) . CDC2 was identified as a component of an MCL proliferation signature (Rosenwald et al., 2003) and as a gene with downregulated expression in SLL compared to reactive lymph node (Schmechel et al., 2004) . BUB1, CDC2, CCNB1, CCNB2, and ZWINT were all identified as genes downregulated in CLL compared to DLBCL, BL, and FL (Klein et al., 2001) . YWHAQ (tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein, zeta polypeptide) was identified as a protein with upregulated expression in MCL compared to normal tonsillar B cells (Ghobrial et al., 2005) . IFI44L (interferon-induced protein 44-like) was identified as a gene with upregulated expression in MCL compared to FL (Schmechel et al., 2004) . Interestingly, both CDC2 and IFI44L did not show up in the specific MCL-SLL microarray, even though they were found in these other array comparisons (Schmechel et al., 2004) , highlighting the ability of SSH to identify differentially expressed genes that standard microarray technologies miss. ENPP2 (Ectonucleotide pyrophosphatase/phosphodiesterase 2) and GLUL (glutamate-ammonia ligase) were identified as genes with upregulated expression in MCL compared to naïve B cells (Ek et al., 2002; Rizzatti et al., 2005) .
Several genes identified in the SLL-MCL SSH direction (SLLspecific genes) have also been identified in microarray studies (see Table 2 ). Most importantly, FCER2 (Fc fragment of IgE, low affinity II, receptor for CD23), also called CD23, is a major diagnostic marker for the classification of SLL and was identified as differentially expressed in SLL and absent from genes identified in the MCL-specific gene pool. RHOH (Ras homolog gene family member H) and GPR183 (G protein-coupled receptor 183) were identified as genes with down-regulated expression in MCL compared to normal tonsillar B cells (Zhu et al., 2001) . NFE2L2 (nuclear factor erythroid-derived 2-like 2) was identified as a gene with downregulated expression in MCL compared to FL (Schmechel et al., 2004) . PAX5 (paired box 5), also called BSAP, was identified as upregulated in CLL compared to tonsillar B cells (Aalto et al., 2001) . The identification of many of the same genes in this study of SLL and in similar microarray studies of indolent lymphoma supports the use of SSH as a technique for successfully identifying differentially expressed genes.
Interestingly, many genes were identified having preferential expression in MCL versus SLL that have not been identified elsewhere that may play a role in the development and progression of MCL and other aggressive malignancies. These genes may not have met the criteria for microarray analysis, but were picked up by SSH due to its ability to detect rare transcripts, even those with modest changes in gene expression (Gadgil et al., 2002) . SSH also picks up differentially expressed sequences that have no matches in the database other than to BAC clones or chromosome open reading frames (ORFs) (Gadgil et al., 2002) . These rare transcripts, modestly expressed genes, and unknown genes should not be overlooked when describing genes associated with certain cell types such as aggressive lymphomas, as any of these may contribute to the aggressive phenotype of these diseases (Gadgil et al., 2002) or provide potentially useful biomarkers in future studies. The identification of all these gene types in our study validate the use and utility of SSH especially for rare mRNA detection.
